123931-04-4
中文名稱
R(+)-3-氨基-1-羥基-2-吡咯烷酮
英文名稱
(R)-(+)-HA-966
CAS
123931-04-4
分子式
C4H8N2O2
分子量
116.12
MOL 文件
123931-04-4.mol
123931-04-4 結(jié)構(gòu)式
基本信息
中文別名
(3R)-3-氨基-1-羥基-2-吡咯烷酮R(+)-3-氨基-1-羥基-2-吡咯烷酮
英文別名
Zinc03791818(R)-(+)-HA-966
R(+)-HA-966 R(+)-3-AMINO-1-HYDROX
(3R)-3-Amino-1-hydroxy-2-pyrrolidinone
R(+)-3-AMINO-1-HYDROXY-2-PYRROLIDINONE
(R)-(+)-3-AMINO-1-HYDROXYPYRROLIDIN-2-ONE
2-Pyrrolidinone, 3-amino-1-hydroxy-, (3R)-
(R)-3-amino-1-hydroxypyrrolidin-2-one 2,2,2-trifluoroacetate
所屬類別
有機原料：雜環(huán)化合物物理化學(xué)性質(zhì)
熔點166℃
沸點258.6±50.0 °C(Predicted)
密度1.436±0.06 g/cm3(Predicted)
儲存條件Desiccate at RT
溶解度H2O: soluble
溶解度可溶于水中
酸度系數(shù)(pKa)7.19±0.20(Predicted)
形態(tài)solid
顏色white
旋光性 (optical activity)[α]22/D +103°, c = 1 in H2O(lit.)
水溶解性溶于水至100mM
R(+)-3-氨基-1-羥基-2-吡咯烷酮價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-100822 | R(+)-3-氨基-1-羥基-2-吡咯烷酮 (R)-(+)-HA-966 | 123931-04-4 | 5 mg | 1100元 |
| 2025/02/08 | HY-100822 | R(+)-3-氨基-1-羥基-2-吡咯烷酮 (R)-(+)-HA-966 | 123931-04-4 | 10 mM * 1 mLin Water | 1210元 |
| 2025/02/08 | HY-100822 | R(+)-3-氨基-1-羥基-2-吡咯烷酮 (R)-(+)-HA-966 | 123931-04-4 | 10 mg | 1760元 |
常見問題列表
生物活性
(R)-(+)-HA-966 ((+)-HA-966) 是 N-甲基-D-天冬氨酸 (NMDA) 受體復(fù)合物的甘氨酸位點的部分激動劑/拮抗劑。(R)-(+)-HA-966 通過苯丙胺選擇性阻斷中腦邊緣多巴胺系統(tǒng)的活化。(R)-(+)-HA-966 可透過血腦屏障，有用于神經(jīng)性和急性疼痛的潛力。靶點
glycine site of the NMDA receptor
體內(nèi)研究
(R)-(+)-HA-966 ((+)-HA-966; 10 mg/kg; IV) significantly attenuates the dose-dependent pressor response and the associated tachycardic response elicited by systemic NMDA (125, 250, 500, and 1000 mg/kg; i.v.).
(+)-HA-966 (30, 100 mg/kg; IP) dose-dependently blocks the enhancement of dopamine synthesis induced in the nucleus accumbens by amphetamine, but is without effect on the increase in dopamine synthesis in the striatum in male BKTO mice (20-30g).
| Animal Model: | Sprague-Dawley rats (11 to 12 weeks old) |
| Dosage: | 10 mg/kg |
| Administration: | IV |
| Result: | Significantly attenuated the dose-dependent pressor response and the associated tachycardic response elicited by systemic NMDA. |